Psilocybin brain scan study completed in healthy adults
NCT ID NCT07050368
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 28 times
Summary
This early-stage study tested multiple doses of MLS101, a low-dose psilocybin drug, in 20 healthy adults aged 18 to 55. Researchers used brain scans (fMRI) to see how the drug affects brain activity and checked for side effects and how the drug moves through the body. The goal was to gather safety and brain data to support future studies for neurological and psychiatric conditions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hammersmith Medicines Research (HMR)
London, NW10 7EW, United Kingdom
Conditions
Explore the condition pages connected to this study.